Neutralization of Zika virus by E protein domain III-Specific human monoclonal antibody

Induction of Anti-Aquaporin 5 Autoantibody Production by Immunization with a Peptide Derived from the Aquaporin of Prevotella melaninogenica Leads to Reduced Salivary Flow in Mice

“…IgG was purified by affinity chromatography using MabSelect columns with the AKTA Pure chromatography system (GE Healthcare, Chicago, IL, USA) following the manufacturer's protocol. An in-house discovered Ab specific to Zika virus envelope domain III ( 27 ) was also produced in human IgG4 format and used as an isotype control.…”

Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin

“…The genes of heavy chain (V H ) and light chain (V L ) variable regions are amplified using reverse transcription-polymerase chain reaction (RT-PCR) from the RNA of antigen-specific memory B cells, which are collected from those who have infected, recovered or vaccinated. scFv and Fab genes are cloned into a phagemid to generate a scFv or Fab library that contains >10 8 V H and V L combinations ( DiGiandomenico et al, 2012 ; Kim et al, 2021 ; Parray et al, 2020 ; Throsby et al, 2008 ). This library is introduced into the phage and expressed on the surface.…”

“…Thus, the E protein is the main target for neutralizing antibodies ( Fig. 3 e) ( Kim et al, 2021 ). The DI/II domain-specific mAb ZKA78 obtained from ZIKV-infected individuals inhibits ZIKV infection in vitro and in vivo.…”

“…et al, 2017, Cell HCV 2A5 GT1b E2 region (conformation-dependent) Human hybridoma in vitro and in vivo (Human liver-chimeric mice model) An individual chronically infected with HCV Isabelle Desombere et al, 2017 , Antiviral Res HCV AR4A 2.9 ± 1.8 outside the CD81-binding site on the E1E2 complex Phage display in vitro A 35-year-old female individual with Sjögren's syndrome and chronic HCV (GT1a) infection Erick Giang et al, 2012 , PNAS, and Rodrigo Velazquez-Moctezuma, et al, 2018, JID HCV AR3A 1.3/1.7 E2 (HCVpp GT1a/2a/4/5) Phage display in vitro and in vivo (Human liver-chimeric mice model) A 35-year-old female individual with Sjögren's syndrome and chronic HCV (GT1a) infection Mansun Law et al, 2008 , Nature medicine AR3B 2.0/2.3 HBV 3 clones HBsAg Antibody-encoding gene sequencing and cloning of HBsAg specific B cells immortalized by EBV in vitro A vaccinated healthy donor and a individual convalescing from acute HBV infection Antonella Cerio, et al, 2015, PLoS ONE ZIKV ZIKV-117 E protein Antibody-encoding gene sequencing and cloning of Memroy B cells immortalized by EBV in vitro and in vivo (IFNAR-blocking C57BL/6 mice model) Healthy individuals who had previously been infected with ZIKV in diverse geographic locations. Gopal Sapparapu et al, 2016 , Nature, S. Saif Hsaan, et al, 2017, Nature comm, and Jesse H. Erasmus et al, 2020 Methods & Clinical Development ZIKV 2F-8 E protein (DIII) Phage display in vitro and in vivo (Ifnar−/− mice model) Two ZIKV-infected individuals at Seoul National University Hospital Sang Il Kim et al, 2021 , BBRC ZIKV ZIKV-195 E protein Antibody-encoding gene sequencing and cloning of Memroy B cells immortalized by EBV in vitro and in vivo (IFNAR-blocking C57BL/6 mice model) ...…”

“… ACE2, angiotensin-converting enzyme 2; AdV-hACE2, replication-defective adenoviruses encoding human ACE2; BCR, B cell receptor; BDBV, Bundibugyo ebolavirus; BTX, botulinum neurotoxin; SUDV, Sudan ebolavirus; COVID-19, Coronavirus Disease 2019; DENV, Dengue virus; DRC, Democratic Republic of the Congo; DT, Diphtheria toxin; EBV, Epstein-Barr virus; EBOV, Ebola virus; EVD, Ebola virus disease; Fab, Fab, fragmented antigen binding region; GP, glycoprotein; GT, genotype; HA, hemagglutinin; HBsAg, hepatitis B virus antigen; HBV, hepatitis B virus, Hc, heavy chain C-terminal receptor binding domain; HCV, hepatitis C virus; HCVpp, pseudotype virus particles HCV; Hn, heavy chain N-terminal translocation domain, IFNAR1, interferon Alpha and Beta receptor subunit 1; IFNR, interferon receptor; i.m., intramuscular injection; KD, dissociation constant; Lc, light chain; NA, neuraminidase; NTD, N-terminal domain; PCR, polymerase chain reaction; PfSPZ, Plasmodium falciparum sporozoite; SARS-CoV, severe acute respiratory syndrome coronavirus; SpA, S. aureus wall moiety Protein A; TeNT, tetanus toxin; TIV, trivalent inactivated influenza vaccine; RBD, receptor binding domain; ZIKV, Zika virus; ZPIV, Z001 Zika purified inactivated virus ( Bangaru et al, 2016 ; Bangaru et al, 2018 ; Barnes et al, 2020 ; Bornholdt et al, 2016 ; Cao et al, 2020 ; Cerino, Bremer, Glebe, & Mondelli, 2015 ; Chen et al, 2020 ; Corti et al, 2011 ; Corti et al, 2016 ; Desombere et al, 2017 ; DiGiandomenico et al, 2012 ; Dreyfus et al, 2012 ; Dussupt et al, 2020 ; Erasmus et al, 2020 ; Fan et al, 2015 ; Flyak et al, 2016 ; Flyak et al, 2018 ; Giang et al, 2012 ; Gilchuk et al, 2018 ; Gilchuk et al, 2019 ; Hansen et al, 2020 ; Hasan et al, 2017 ; Hu et al, 2019 ; Huo et al, 2020 ; Hurlburt et al, 2020 ; Ju et al, 2020 ; Kallewaard et al, 2016 ; Kim et al, 2021 ; Kisalu et al, 2018 ; Law et al, 2008 ; Li et al, 2012 ; Long et al, 2019 ; Minamitani et al, 2021 ; Nachbagauer et al, 2018 ; …”